Full text
Earnings transcript
Read the complete earnings call transcript.
IVA
IVA
Inventiva S.A.
$2.87
-0.25
(-8.01%)
| Exchange: | NASDAQ |
| Market Cap: | 149.189M |
| Shares Outstanding: | 33.875M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | BiotechnologyView industry performance | |||||
| CEO: | Andrew Obenshain | |||||
| Full Time Employees: | 77 | |||||
| Address: |
| |||||
| Website: | https://www.inventivapharma.com |
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company’s most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Click to read more…
Revenue Segmentation
IVA full analysis
Hey everyone, welcome back to MarketSnap. Inventiva just reported earnings and the stock moved hard — down double digits in the last month alone — and the market has already voted with its feet. So our job today is to check whether that reaction actually matches the updated fundamentals. We're rerunning IVA through the full MarketSnap breakdown with the fresh numbers. Now, if you're new to this name, let me frame it properly. Inventiva is a clinical-stage biopharmaceutical company out…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 17,477 | 9,198 | 4,483 |
| Gross Profit | 17,500 | 9,198 | 1,509.956 |
| EBITDA | -102,041 | -166,525 | -127,723.540 |
| Operating Income | -102,709 | -97,558 | -130,946.540 |
| Net Income | -110,426 | -184,212 | -340,161.126 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 69,561 | 118,967 | 248,879.030 |
| Total Liabilities | 101,593 | 225,613 | 277,914.667 |
| Total Stockholders Equity | -32,032 | -106,646 | -29,035.636 |
| Total Debt | 37,489 | 54,329 | 59,397.708 |
| Cash and Cash Equivalents | 26,918 | 96,563 | 99,269.731 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -81,614 | -85,928 | -100,982.723 |
| Capital Expenditure | -540 | -333 | -237.255 |
| Free Cash Flow | -82,154 | -86,261 | -101,219.978 |
| Net Income | -110,426 | -184,212 | -340,161.126 |
| Net Change in Cash | -59,818 | 69,646 | 14,166.522 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 647,773.244 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 647,773.244 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 647,773.244 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 170,220.677 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 170,220.677 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 170,220.677 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 111,068.610 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 111,068.610 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 111,068.610 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 2,434,650.634 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 2,434,650.634 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 2,434,650.634 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 0.590 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 0.590 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 0.590 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 5 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Diversified revenue base across multiple product categories and geographic regions, reducing dependence on any single market or segment.
- Positive operating cash flow and free cash flow generation, supported by consistent net income and EBITDA levels across recent fiscal periods.
- Manageable leverage profile, with debt-to-equity and current/quick ratios indicating adequate short-term liquidity and solvency.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates IVA intrinsic value between $8.05 – $11.66 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about IVA valuation
Is Inventiva S.A. (IVA) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Inventiva S.A. (IVA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is IVA a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IVA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is IVA’s P/E ratio?
You can see IVA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for IVA?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is IVA a good long-term investment?
Whether IVA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
IVA
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-8.01
Trading Metrics:
| Open: | 3.03 | Previous Close: | 3.12 | |
| Day Low: | 2.87 | Day High: | 3.03 | |
| Year Low: | 2.87 | Year High: | 7.98 | |
| Price Avg 50: | 4.17 | Price Avg 200: | 4.99 | |
| Volume: | 2.508M | Average Volume: | 1.449M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
